Compare RLX Technology Inc (RLX) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? RLX Technology Inc trades at $1.73 (market cap $2.11B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 27.6× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.78%). Which is the better fit depends on your goals — on Pluang, investors hold RLX Technology Inc for 34 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| RLX | TAK | |
|---|---|---|
Market Cap | $2.11B | $58.16B |
Volume | 621,808 | 2,467,530 |
Sector | Consumer Staples | Health |
52-Week High | $2.57 | $19.05 |
52-Week Low | $1.68 | $13.23 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $844.50M | $86.04B |
Dividend Yield | 5.78% | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX Technology trades at $1.73, down 1.76% with a bearish technical signal. The stock recently hit 52-week lows amid margin compression despite 14.8% revenue growth in Q2 2026. Valuation appears reasonable with P/E of 15.55 and P/B below 1, but earnings misses in recent quarters raise execution concerns. International expansion now drives 70% of revenue following European acquisitions.
The outlook remains challenged by consecutive earnings misses and technical weakness, though discounted valuation and international growth provide potential upside. Key risks include sustained margin pressure and integration challenges from recent acquisitions. With only one analyst covering and maintaining a hold rating, institutional conviction appears limited.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
